Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1999 1
2000 1
2004 3
2005 3
2006 2
2007 2
2008 3
2009 3
2010 6
2011 4
2012 10
2013 7
2014 19
2015 9
2016 15
2017 18
2018 27
2019 31
2020 30
2021 30
2022 23
2023 20
2024 9

Text availability

Article attribute

Article type

Publication date

Search Results

244 results

Results by year

Filters applied: . Clear all
Quoted phrase not found in phrase index: "Breast cancer, susceptibility to"
Page 1
EAU-EANM-ESTRO-ESUR-SIOG Guidelines on Prostate Cancer-2020 Update. Part 1: Screening, Diagnosis, and Local Treatment with Curative Intent.
Mottet N, van den Bergh RCN, Briers E, Van den Broeck T, Cumberbatch MG, De Santis M, Fanti S, Fossati N, Gandaglia G, Gillessen S, Grivas N, Grummet J, Henry AM, van der Kwast TH, Lam TB, Lardas M, Liew M, Mason MD, Moris L, Oprea-Lager DE, van der Poel HG, Rouvière O, Schoots IG, Tilki D, Wiegel T, Willemse PM, Cornford P. Mottet N, et al. Eur Urol. 2021 Feb;79(2):243-262. doi: 10.1016/j.eururo.2020.09.042. Epub 2020 Nov 7. Eur Urol. 2021. PMID: 33172724
Risk-adapted screening should be offered to men at increased risk from the age of 45 yr and to breast cancer susceptibility gene (BRCA) mutation carriers, who have been confirmed to be at risk of early and aggressive disease (mainly BRAC2), from around …
Risk-adapted screening should be offered to men at increased risk from the age of 45 yr and to breast cancer susceptibility …
Benefits and Harms of Breast Cancer Screening: A Systematic Review.
Myers ER, Moorman P, Gierisch JM, Havrilesky LJ, Grimm LJ, Ghate S, Davidson B, Mongtomery RC, Crowley MJ, McCrory DC, Kendrick A, Sanders GD. Myers ER, et al. JAMA. 2015 Oct 20;314(15):1615-34. doi: 10.1001/jama.2015.13183. JAMA. 2015. PMID: 26501537 Review.
IMPORTANCE: Patients need to consider both benefits and harms of breast cancer screening. OBJECTIVE: To systematically synthesize available evidence on the association of mammographic screening and clinical breast examination (CBE) at different ages and inter …
IMPORTANCE: Patients need to consider both benefits and harms of breast cancer screening. OBJECTIVE: To systematically synthes …
Male breast cancer: risk factors, biology, diagnosis, treatment, and survivorship.
Ruddy KJ, Winer EP. Ruddy KJ, et al. Ann Oncol. 2013 Jun;24(6):1434-43. doi: 10.1093/annonc/mdt025. Epub 2013 Feb 20. Ann Oncol. 2013. PMID: 23425944 Free article. Review.
BACKGROUND: The causes, optimal treatments, and medical/psychosocial sequelae of breast cancer in men are poorly understood. DESIGN: A systematic review of the English language literature was conducted to identify studies relevant to male breast cancer …
BACKGROUND: The causes, optimal treatments, and medical/psychosocial sequelae of breast cancer in men are poorly understood. D …
Peutz-Jeghers syndrome: a systematic review and recommendations for management.
Beggs AD, Latchford AR, Vasen HF, Moslein G, Alonso A, Aretz S, Bertario L, Blanco I, Bülow S, Burn J, Capella G, Colas C, Friedl W, Møller P, Hes FJ, Järvinen H, Mecklin JP, Nagengast FM, Parc Y, Phillips RK, Hyer W, Ponz de Leon M, Renkonen-Sinisalo L, Sampson JR, Stormorken A, Tejpar S, Thomas HJ, Wijnen JT, Clark SK, Hodgson SV. Beggs AD, et al. Gut. 2010 Jul;59(7):975-86. doi: 10.1136/gut.2009.198499. Gut. 2010. PMID: 20581245
The majority of patients that meet the clinical diagnostic criteria have a causative mutation in the STK11 gene, which is located at 19p13.3. The cancer risks in this condition are substantial, particularly for breast and gastrointestinal cancer, although asc …
The majority of patients that meet the clinical diagnostic criteria have a causative mutation in the STK11 gene, which is located at 19p13.3 …
Germline Testing in Patients With Breast Cancer: ASCO-Society of Surgical Oncology Guideline.
Bedrosian I, Somerfield MR, Achatz MI, Boughey JC, Curigliano G, Friedman S, Kohlmann WK, Kurian AW, Laronga C, Lynce F, Norquist BS, Plichta JK, Rodriguez P, Shah PD, Tischkowitz M, Wood M, Yadav S, Yao K, Robson ME. Bedrosian I, et al. J Clin Oncol. 2024 Feb 10;42(5):584-604. doi: 10.1200/JCO.23.02225. Epub 2024 Jan 4. J Clin Oncol. 2024. PMID: 38175972
All patients with recurrent breast cancer who are candidates for PARP inhibitor therapy should be offered BRCA1/2 testing, regardless of family history. BRCA1/2 testing should be offered to women who develop a second primary cancer in the ipsilateral or contr …
All patients with recurrent breast cancer who are candidates for PARP inhibitor therapy should be offered BRCA1/2 testing, reg …
Risk-reducing mastectomy for the prevention of primary breast cancer.
Carbine NE, Lostumbo L, Wallace J, Ko H. Carbine NE, et al. Cochrane Database Syst Rev. 2018 Apr 5;4(4):CD002748. doi: 10.1002/14651858.CD002748.pub4. Cochrane Database Syst Rev. 2018. PMID: 29620792 Free PMC article. Review.
OBJECTIVES: (i) To determine whether risk-reducing mastectomy reduces death rates from any cause in women who have never had breast cancer and in women who have a history of breast cancer in one breast, and (ii) to examine the effect of risk-red …
OBJECTIVES: (i) To determine whether risk-reducing mastectomy reduces death rates from any cause in women who have never had breast …
Hormone replacement therapy in BRCA mutation carriers and risk of ovarian, endometrial, and breast cancer: a systematic review.
Huber D, Seitz S, Kast K, Emons G, Ortmann O. Huber D, et al. J Cancer Res Clin Oncol. 2021 Jul;147(7):2035-2045. doi: 10.1007/s00432-021-03629-z. Epub 2021 Apr 22. J Cancer Res Clin Oncol. 2021. PMID: 33885953 Free PMC article.
Hormone replacement therapy (HRT) may increase breast, ovarian, and endometrial cancer risk in the general population. ...For ovarian cancer, results were ambiguous. For breast cancer, most studies did not find an adverse effect associated with …
Hormone replacement therapy (HRT) may increase breast, ovarian, and endometrial cancer risk in the general population. ...For …
The Molecular Mechanisms of Actions, Effects, and Clinical Implications of PARP Inhibitors in Epithelial Ovarian Cancers: A Systematic Review.
Lau CH, Seow KM, Chen KH. Lau CH, et al. Int J Mol Sci. 2022 Jul 23;23(15):8125. doi: 10.3390/ijms23158125. Int J Mol Sci. 2022. PMID: 35897700 Free PMC article. Review.
Ovarian cancer is the most lethal gynecologic malignancy in the United States. Some patients affected by ovarian cancers often present genome instability with one or more of the defects in DNA repair pathways, particularly in homologous recombination (HR), which is strictl …
Ovarian cancer is the most lethal gynecologic malignancy in the United States. Some patients affected by ovarian cancers often presen …
Poly(ADP-ribose) polymerase (PARP) inhibitors for the treatment of ovarian cancer.
Tattersall A, Ryan N, Wiggans AJ, Rogozińska E, Morrison J. Tattersall A, et al. Cochrane Database Syst Rev. 2022 Feb 16;2(2):CD007929. doi: 10.1002/14651858.CD007929.pub4. Cochrane Database Syst Rev. 2022. PMID: 35170751 Free PMC article. Review.
BACKGROUND: Ovarian cancer is the sixth most common cancer in women world-wide. Epithelial ovarian cancer (EOC) is the most common; three-quarters of women present when disease has spread outside the pelvis (stage III or IV). ...Although initial respon …
BACKGROUND: Ovarian cancer is the sixth most common cancer in women world-wide. Epithelial ovarian cancer (EOC) is the …
Penetrance of male breast cancer susceptibility genes: a systematic review.
Chamseddine RS, Wang C, Yin K, Wang J, Singh P, Zhou J, Robson ME, Braun D, Hughes KS. Chamseddine RS, et al. Breast Cancer Res Treat. 2022 Jan;191(1):31-38. doi: 10.1007/s10549-021-06413-2. Epub 2021 Oct 13. Breast Cancer Res Treat. 2022. PMID: 34642874 Review.
PURPOSE: Several male breast cancer (MBC) susceptibility genes have been identified, but the MBC risk for individuals with a pathogenic variant in each of these genes (i.e., penetrance) remains unclear. We conducted a systematic review of studies reporting th …
PURPOSE: Several male breast cancer (MBC) susceptibility genes have been identified, but the MBC risk for individuals w …
244 results